149 related articles for article (PubMed ID: 11176764)
1. Use of a fixed activated partial thromboplastin time ratio to establish a therapeutic range for unfractionated heparin.
Bates SM; Weitz JI; Johnston M; Hirsh J; Ginsberg JS
Arch Intern Med; 2001 Feb; 161(3):385-91. PubMed ID: 11176764
[TBL] [Abstract][Full Text] [Related]
2. Establishing a new target range for unfractionated heparin for acute coronary syndromes.
Lee MS; Menon V; Schappert J; Wilentz JR; Singh V; Hochman JS
J Thromb Thrombolysis; 2004 Apr; 17(2):121-6. PubMed ID: 15306747
[TBL] [Abstract][Full Text] [Related]
3. Monitoring heparin therapy using activated partial thromboplastin time--results of a multicenter trial establishing the therapeutic range for SILIMAT, a reagent with high sensitivity to heparin.
Toulon P; Boutière B; Horellou MH; Trzeciak MC; Samama MM
Thromb Haemost; 1998 Jul; 80(1):104-8. PubMed ID: 9684794
[TBL] [Abstract][Full Text] [Related]
4. The therapeutic range for heparin therapy: relationship between six activated partial thromboplastin time reagents and two heparin assays.
Kitchen S; Preston FE
Thromb Haemost; 1996 May; 75(5):734-9. PubMed ID: 8725715
[TBL] [Abstract][Full Text] [Related]
5. Monitoring of unfractionated heparin with the activated partial thromboplastin time: determination of therapeutic ranges.
van den Besselaar AM; Sturk A; Reijnierse GL
Thromb Res; 2002 Sep; 107(5):235-40. PubMed ID: 12479884
[TBL] [Abstract][Full Text] [Related]
6. APTT therapeutic range for monitoring unfractionated heparin therapy. Significant impact of the anti-Xa reagent used for correlation.
Toulon P; Smahi M; De Pooter N
J Thromb Haemost; 2021 Aug; 19(8):2002-2006. PubMed ID: 33555096
[TBL] [Abstract][Full Text] [Related]
7. Effect of clot-detection methods and reagents on activated partial thromboplastin time (APTT). Implications in heparin monitoring by APTT.
D'Angelo A; Seveso MP; D'Angelo SV; Gilardoni F; Dettori AG; Bonini P
Am J Clin Pathol; 1990 Sep; 94(3):297-306. PubMed ID: 2396604
[TBL] [Abstract][Full Text] [Related]
8. Activated partial thromboplastin time versus antifactor Xa heparin assay in monitoring unfractionated heparin by continuous intravenous infusion.
Guervil DJ; Rosenberg AF; Winterstein AG; Harris NS; Johns TE; Zumberg MS
Ann Pharmacother; 2011 Jul; 45(7-8):861-8. PubMed ID: 21712506
[TBL] [Abstract][Full Text] [Related]
9. Antifactor Xa levels vs. activated partial thromboplastin time for monitoring unfractionated heparin. A pilot study.
Samuel S; Allison TA; Sharaf S; Yau G; Ranjbar G; Mckaig N; Nguyen A; Escobar M; Choi HA
J Clin Pharm Ther; 2016 Oct; 41(5):499-502. PubMed ID: 27381025
[TBL] [Abstract][Full Text] [Related]
10. Monitoring heparin therapy: relationships between the activated partial thromboplastin time and heparin assays based on ex-vivo heparin samples.
van den Besselaar AM; Meeuwisse-Braun J; Bertina RM
Thromb Haemost; 1990 Feb; 63(1):16-23. PubMed ID: 2339357
[TBL] [Abstract][Full Text] [Related]
11. Activated partial thromboplastin time and anti-xa measurements in heparin monitoring: biochemical basis for discordance.
Takemoto CM; Streiff MB; Shermock KM; Kraus PS; Chen J; Jani J; Kickler T
Am J Clin Pathol; 2013 Apr; 139(4):450-6. PubMed ID: 23525615
[TBL] [Abstract][Full Text] [Related]
12. Retrospective cohort study comparing activated partial thromboplastin time versus anti-factor Xa activity nomograms for therapeutic unfractionated heparin monitoring in pediatrics.
Trucco M; Lehmann CU; Mollenkopf N; Streiff MB; Takemoto CM
J Thromb Haemost; 2015 May; 13(5):788-94. PubMed ID: 25740425
[TBL] [Abstract][Full Text] [Related]
13. Antifactor Xa levels versus activated partial thromboplastin time for monitoring unfractionated heparin.
Vandiver JW; Vondracek TG
Pharmacotherapy; 2012 Jun; 32(6):546-58. PubMed ID: 22531940
[TBL] [Abstract][Full Text] [Related]
14. [Correlation between aPTT and antifactor Xa to determine therapeutic ranges for unfractionated heparin].
Mariné L; Sánchez G; Vargas JF; Zúñiga P; Aizman A; Mertens R; Bergoeing M; Muñoz B
Rev Med Chil; 2014 Nov; 142(11):1392-7. PubMed ID: 25694284
[TBL] [Abstract][Full Text] [Related]
15. Establishing a therapeutic range for heparin therapy.
Brill-Edwards P; Ginsberg JS; Johnston M; Hirsh J
Ann Intern Med; 1993 Jul; 119(2):104-9. PubMed ID: 8512158
[TBL] [Abstract][Full Text] [Related]
16. The effect of calcium ions on the activated partial thromboplastin time of heparinized plasma.
Greenberg CS; Adams JP; Mullen PE; Koepke JA
Am J Clin Pathol; 1986 Oct; 86(4):484-9. PubMed ID: 3766461
[TBL] [Abstract][Full Text] [Related]
17. Comparison of anti-factor Xa heparin activity and activated partial thromboplastin time in 2,773 plasma samples from unfractionated heparin-treated patients.
Rosborough TK
Am J Clin Pathol; 1997 Dec; 108(6):662-8. PubMed ID: 9384448
[TBL] [Abstract][Full Text] [Related]
18. Activated Partial Thromboplastin Time Monitoring of Unfractionated Heparin Therapy: Issues and Recommendations.
Marlar RA; Clement B; Gausman J
Semin Thromb Hemost; 2017 Apr; 43(3):253-260. PubMed ID: 27272964
[TBL] [Abstract][Full Text] [Related]
19. Establishing an institution-specific therapeutic range for heparin.
Volles DF; Ancell CJ; Michael KA; Mullins DM; Humphries JE
Am J Health Syst Pharm; 1998 Oct; 55(19):2002-6. PubMed ID: 9784787
[TBL] [Abstract][Full Text] [Related]
20. Variability in heparin sensitivity of APTT reagents.
Bjornsson TD; Nash PV
Am J Clin Pathol; 1986 Aug; 86(2):199-204. PubMed ID: 3739971
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
